| Current Price | $8.98 | Mkt Cap | $323.7M |
|---|---|---|---|
| Open | $9.13 | P/E Ratio | 0.00 |
| Prev. Close | $8.98 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $8.84 - $9.45 | Volume | 258,545 |
| 52-Wk Range | $3.68 - $10.38 | Avg. Daily Vol. | 674,459 |
| Current Price | $8.98 | Mkt Cap | $323.7M |
|---|---|---|---|
| Open | $9.13 | P/E Ratio | 0.00 |
| Prev. Close | $8.98 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $8.84 - $9.45 | Volume | 258,545 |
| 52-Wk Range | $3.68 - $10.38 | Avg. Daily Vol. | 674,459 |
The best Bull and Bear pitches based on recency and number of recommendations.
This is basically a bet on Furoscix. SCPH is billing this as an $8B market. Even if you turn the BS radar on, the potential is still dramatic compared to SCPH's market cap. If they manage to garner only $200-300M in sales they could be looking at a… More
The best thing you can say about this company is that it does have a decent amount of cash still to burn through. But the thing is, there's no short-term prospect of being cash-flow positive judging by the financials. There are dozens if not hundreds… More
Read the most recent pitches from players about SCPH.
Recs
odocoileus
(42.40)
Submitted: 1/26/2020 1:47:36 AM :
Start Price:
$11.17
NASDAQ:SCPH Score:
-72.33
This is basically a bet on Furoscix. SCPH is billing this as an $8B market. Even if you turn the BS radar on, the potential is still dramatic compared to SCPH's market cap. If they manage to garner only $200-300M in sales they could be looking at a $1B market cap. This seems easily doable. Even with almost certain dilution, the increase in share price would be significant. The question is, how likely are they to gain FDA approval? I got burned by green thumbing them before the last CRL. I believe they will make it through this next round. So if after your DD you believe they will make it through the FDA process, there are two ways to play this: Take a flyer and hope for a run up to approval, or pucker up and hold on for dear life. Either way, I think taking a flyer with money you can afford to lose could lead to some outsized gains. They are planning on having their submission complete by June. For a company that is a year or so away from a viable product, I think it is undervalued.
Recs
oscillation
(73.23)
Submitted: 2/22/2019 1:17:32 AM :
Start Price:
$3.23
NASDAQ:SCPH Score:
+131.85
nev
Find the members with the highest scoring picks in SCPH.
HDTVBG (< 20) Score: +165.60
The Score Leader is the player with the highest score across all their picks in SCPH.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| oscillation | 73.23 | 2/22/2019 |
|
5Y | $3.23 | +177.01% | +45.17% | +131.85 | 1 Comment | |
| ababrmon | 46.74 | 10/3/2022 |
|
5Y | $5.95 | +50.59% | +10.93% | +39.66 | 0 Comment | |
| eagles777 | 66.91 | 3/20/2023 |
|
5Y | $6.91 | +29.67% | +3.31% | +26.36 | 0 Comment | |
| PAGEBOY73 | 98.38 | 12/29/2022 |
|
3W | $6.90 | +29.86% | +5.16% | +24.69 | 0 Comment | |
| Smiley81 | < 20 | 10/28/2019 |
|
5Y | $5.86 | +52.90% | +33.27% | -19.63 | 0 Comment | |
| Under5b | < 20 | 12/23/2022 |
|
5Y | $6.38 | +40.44% | +6.34% | -34.10 | 0 Comment | |
| PAGEBOY54 | 93.26 | 12/28/2022 |
|
NS | $6.33 | +41.48% | +5.67% | -35.81 | 0 Comment | |
| johnnyrocku | 99.94 | 11/12/2018 |
|
5Y | $4.85 | +84.74% | +45.65% | -39.09 | 0 Comment | |
| liszewski | 99.97 | 11/12/2018 |
|
5Y | $4.85 | +84.74% | +45.65% | -39.09 | 0 Comment | |
| TheGreatSatan | 99.97 | 7/12/2022 |
|
5Y | $5.31 | +68.74% | +5.23% | -63.51 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
